Literature DB >> 24384827

Revising DAS28 scores for remission in rheumatoid arthritis.

Claire Sheehy1, Verity Evans, Heather Hasthorpe, Chetan Mukhtyar.   

Abstract

Current initiatives to treat rheumatoid arthritis (RA) to target remission have resulted in the widespread use of composite outcome measures to quantify disease activity. Simplified Disease Activity Index (SDAI) ≤3.3 is the gold standard of remission. Previous work has suggested that the remission threshold of DAS28-ESR or DAS28-CRP ≤2.6 is known to be not strict enough and should be revised. There is no previous study that looks at the equivalent DAS28-CRP value that best reflects SDAI remission in a real-life cohort. Consecutive cases fulfilling ACR/EULAR classification criteria for RA from one centre were included if they had an optimum number of visits with recording of all raw data to calculate DAS28-ESR, DAS28-CRP and SDAI. Data from seven visits each of 76 patients, providing 532 data points was examined. Spearman's correlation between DAS28-ESR, DAS28-CRP and SDAI was 0.91-0.97 (p < 0.001). A Bland-Altman plot demonstrated a mean difference of 0.37 units between DAS28-ESR and DAS28-CRP (p < 0.001). ROC and kappa analysis provided values of 2.58 and 2.55 for DAS28-ESR4V and 2.09 and 2.05 for DAS28-CRP4V for SDAI value of 3.3, respectively. The two versions of DAS28 using ESR and CRP and SDAI correlate but are not equivalent or interchangeable for an individual patient. The DAS28-CRP overestimates remission and should be revised downwards to a proposed value of 2.1.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24384827     DOI: 10.1007/s10067-013-2468-z

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  21 in total

1.  2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative.

Authors:  Daniel Aletaha; Tuhina Neogi; Alan J Silman; Julia Funovits; David T Felson; Clifton O Bingham; Neal S Birnbaum; Gerd R Burmester; Vivian P Bykerk; Marc D Cohen; Bernard Combe; Karen H Costenbader; Maxime Dougados; Paul Emery; Gianfranco Ferraccioli; Johanna M W Hazes; Kathryn Hobbs; Tom W J Huizinga; Arthur Kavanaugh; Jonathan Kay; Tore K Kvien; Timothy Laing; Philip Mease; Henri A Ménard; Larry W Moreland; Raymond L Naden; Theodore Pincus; Josef S Smolen; Ewa Stanislawska-Biernat; Deborah Symmons; Paul P Tak; Katherine S Upchurch; Jirí Vencovský; Frederick Wolfe; Gillian Hawker
Journal:  Arthritis Rheum       Date:  2010-09

2.  The many myths of erythrocyte sedimentation rate and C-reactive protein.

Authors:  Frederick Wolfe
Journal:  J Rheumatol       Date:  2009-08       Impact factor: 4.666

3.  Efficacy of tests used to monitor rheumatoid arthritis.

Authors:  B S Bull; J C Westengard; M Farr; P A Bacon; P J Meyer; J Stuart
Journal:  Lancet       Date:  1989-10-21       Impact factor: 79.321

4.  Statistical methods for assessing agreement between two methods of clinical measurement.

Authors:  J M Bland; D G Altman
Journal:  Lancet       Date:  1986-02-08       Impact factor: 79.321

5.  Comparison of Disease Activity Score (DAS)28- erythrocyte sedimentation rate and DAS28- C-reactive protein threshold values.

Authors:  Eisuke Inoue; Hisashi Yamanaka; Masako Hara; Taisuke Tomatsu; Naoyuki Kamatani
Journal:  Ann Rheum Dis       Date:  2006-08-22       Impact factor: 19.103

6.  DAS28 and Rheumatoid Arthritis: The Need for Standardization.

Authors:  Duncan Porter; Kate Gadsby; Paul Thompson; Jo White; Catherine McClinton; Sue Oliver
Journal:  Musculoskeletal Care       Date:  2011-10-04

7.  A simplified disease activity index for rheumatoid arthritis for use in clinical practice.

Authors:  J S Smolen; F C Breedveld; M H Schiff; J R Kalden; P Emery; G Eberl; P L van Riel; P Tugwell
Journal:  Rheumatology (Oxford)       Date:  2003-02       Impact factor: 7.580

8.  Influence of age and gender on the 28-joint Disease Activity Score (DAS28) in rheumatoid arthritis.

Authors:  B J Radovits; J Fransen; P L C M van Riel; R F J M Laan
Journal:  Ann Rheum Dis       Date:  2007-10-27       Impact factor: 19.103

9.  Disease Activity Score 28 (DAS28) using C-reactive protein underestimates disease activity and overestimates EULAR response criteria compared with DAS28 using erythrocyte sedimentation rate in a large observational cohort of rheumatoid arthritis patients in Japan.

Authors:  Toshihiro Matsui; Yoshiaki Kuga; Atsushi Kaneko; Jinju Nishino; Yoshito Eto; Noriyuki Chiba; Masayuki Yasuda; Koichiro Saisho; Kota Shimada; Shigeto Tohma
Journal:  Ann Rheum Dis       Date:  2007-03-16       Impact factor: 19.103

10.  American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials.

Authors:  David T Felson; Josef S Smolen; George Wells; Bin Zhang; Lilian H D van Tuyl; Julia Funovits; Daniel Aletaha; Cornelia F Allaart; Joan Bathon; Stefano Bombardieri; Peter Brooks; Andrew Brown; Marco Matucci-Cerinic; Hyon Choi; Bernard Combe; Maarten de Wit; Maxime Dougados; Paul Emery; Daniel Furst; Juan Gomez-Reino; Gillian Hawker; Edward Keystone; Dinesh Khanna; John Kirwan; Tore K Kvien; Robert Landewé; Joachim Listing; Kaleb Michaud; Emilio Martin-Mola; Pamela Montie; Theodore Pincus; Pamela Richards; Jeffrey N Siegel; Lee S Simon; Tuulikki Sokka; Vibeke Strand; Peter Tugwell; Alan Tyndall; Desirée van der Heijde; Suzan Verstappen; Barbara White; Frederick Wolfe; Angela Zink; Maarten Boers
Journal:  Arthritis Rheum       Date:  2011-03
View more
  8 in total

Review 1.  [Treat to target and personalized medicine (precision medicine)].

Authors:  J Detert; G R Burmester
Journal:  Z Rheumatol       Date:  2016-08       Impact factor: 1.372

2.  Development and validation of equations for conversion from DAS28ESR and DAS28CRP to the SDAI in patients with rheumatoid arthritis.

Authors:  Li-Ming Pu; Yin Liu; De-Xin Zhou; Xi-Jia Tang; Chao-Nan Fan; Wen Chen; Jian-da Ma; Jian-Zi Lin; Lie Dai; Li Ling
Journal:  Clin Rheumatol       Date:  2022-08-10       Impact factor: 3.650

3.  Peripheral Blood Lymphocyte Phenotype Differentiates Secondary Antibody Deficiency in Rheumatic Disease from Primary Antibody Deficiency.

Authors:  Alexandra Jablonka; Haress Etemadi; Ignatius Ryan Adriawan; Diana Ernst; Roland Jacobs; Sabine Buyny; Torsten Witte; Reinhold Ernst Schmidt; Faranaz Atschekzei; Georgios Sogkas
Journal:  J Clin Med       Date:  2020-04-07       Impact factor: 4.241

4.  Serum Reactive Oxygen Metabolites as a Predictor of Clinical Disease Activity Index, Simplified Disease Activity Index, and Boolean Remissions in Rheumatoid Arthritis Patients Treated With Biologic Agents.

Authors:  Arata Nakajima; Keiichiro Terayama; Masato Sonobe; Yorikazu Akatsu; Junya Saito; Masaki Norimoto; Shinji Taniguchi; Ayako Kubota; Yasuchika Aoki; Koichi Nakagawa
Journal:  Cureus       Date:  2021-11-19

5.  Methodological issues in the design of a rheumatoid arthritis activity score and its cut-offs.

Authors:  Olivier Collignon
Journal:  Clin Epidemiol       Date:  2014-07-10       Impact factor: 4.790

6.  Patient and physician perspectives of hand function in a cohort of rheumatoid arthritis patients: the impact of disease activity.

Authors:  Ana K Romero-Guzmán; Víctor M Menchaca-Tapia; Irazú Contreras-Yáñez; Virginia Pascual-Ramos
Journal:  BMC Musculoskelet Disord       Date:  2016-09-15       Impact factor: 2.362

7.  Effects of Achieving Target Measures in Rheumatoid Arthritis on Functional Status, Quality of Life, and Resource Utilization: Analysis of Clinical Practice Data.

Authors:  Evo Alemao; Seongjung Joo; Hugh Kawabata; Maiwenn J Al; Paul D Allison; Maureen P M H Rutten-van Mölken; Michelle L Frits; Christine K Iannaccone; Nancy A Shadick; Michael E Weinblatt
Journal:  Arthritis Care Res (Hoboken)       Date:  2016-03       Impact factor: 4.794

8.  Intensive therapy and remissions in rheumatoid arthritis: a systematic review.

Authors:  Catherine D Hughes; David L Scott; Fowzia Ibrahim
Journal:  BMC Musculoskelet Disord       Date:  2018-10-30       Impact factor: 2.362

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.